Re-Earning the Public Trust
This article was originally published in RPM Report
Executive Summary
Pharma has made big changes in marketing and promotion practices and the systems to assure compliance, but the industry’s ethical image is lagging the efforts at reform. Pfizer Specialty Care/Oncology President Geno Germano says a shared commitment among companies to convince the public of the impact of the industry’s compliance reforms is the key to a healthy environment for the industry.
You may also be interested in...
GSK Leads the Way to Needed Change in Sales Reps Compensation
Will other companies follow a model that can increase trust?
Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks
Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.
Public Interest/Private Sector: Perspectives on Conflict of Interest
Conflict of interest remains a thorny topic in the conduct, analysis and dissemination of clinical trials. Four panelists on a recent Windhover Webinar offer their perspectives on how private companies can best align with the public interest goals of medical research.